Gadgeel et al. [37] studied the effect of genistein in combination with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), erlotinib and gefitinib on NSCLC cell lines with various EGFR mutations and sensitivities to EGFR-TKIs, H3255, H1650, and H1781 (wild-type EGFR). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.